ProMetic's PBI-4050 Anti-Fibrotic Effect Confirmed on Human Kidney Cells

LAVAL, QUEBEC--(Jun 1, 2015) - ProMetic Life Sciences Inc. (TSX:PLI) (OTCQX:PFSCF), ("ProMetic" or the "Corporation") presented new data at the European Renal Association (ERA) annual meeting in London, UK. The new data confirms that PBI-4050's anti-fibrotic effect demonstrated in the kidney in several different animal models has been successfully reproduced in human kidney cell lines during in vitro experiments.

The data presented at the ERA annual meeting summarizes the effect of PBI-4050 on Normal Human Dermal Fibroblasts ("NHDF") and Human Epithelial Proximal Tubule Cells (HK-2) ("human kidney cells") in in vitro experiments designed to simulate fibrosis. PBI-4050 was found to regulate the pro-fibrotic growth factors and the remodeling enzymes in both the NHDF and human kidney cells in the same manner as observed in animals.

OXiGENE Receives Guidance from FDA Supporting Phase 3 Trial of Fosbretabulin/Bevacizumab Combination in Platinum-Resistant Ovarian Cancer

SOUTH SAN FRANCISCO, Calif., June 1, 2015 -- OXiGENE, Inc. (OXGN), a biopharmaceutical company developing novel therapies for the treatment of cancer, today provided an update on recent discussions with the U.S. Food and Drug Administration (FDA) regarding the design of a proposed Phase 3 trial of fosbretabulin in combination with bevacizumab in patients with platinum-resistant ovarian cancer.

• FDA agreed with the company's proposal to test the combination anti-vascular regimen of fosbretabulin and bevacizumab directly against chemotherapy using progression-free survival (PFS) as the primary endpoint in a randomized, controlled registration trial.
• FDA requested inclusion of a third arm, of bevacizumab alone, in the trial to further characterize the efficacy of each individual drug in the combination.
• OXiGENE intends to submit an application to the FDA for a Special Protocol Assessment (SPA) later this year.

  Published: 01 June 2015

  Written by Editor

  Nasdaq   FDA HC Decision   Up on News  

  Read more: OXiGENE Inc ( OXGN )

Oncothyreon Announces Presentation of Positive ONT-380 Data in HER2-Positive Breast Cancer at ASCO Annual Meeting and Updates Development Plan

SEATTLE, May 30, 2015 -- Oncothyreon Inc. (ONTY) today announced the presentation of positive data from the company's ongoing trials of ONT-380, an orally active, reversible and selective small-molecule HER2 inhibitor for the treatment of breast cancer, at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting. The first presentation updated data from the Phase 1b trial of ONT-380 in combination with Xeloda(R) (capecitabine)and Herceptin(R) (trastuzumab) in third line treatment of HER2-positive metastatic breast cancer. The data support Oncothyreon's plans to initiate a blinded, randomized, placebo-controlled Phase 2 trial in this indication. The second presentation focused on the role of ONT-380 in the treatment of HER2-positive breast cancer central nervous system (CNS) metastases.

Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015

Study demonstrates improvement in key disease measurements and disease-related symptoms with pacritinib treatment compared to best available therapy, regardless of platelet levels at the time of enrollment
Treatment resulted in improvements in severe thrombocytopenia and severe anemia, eliminating the need for blood transfusions in a quarter of patients who were transfusion dependent at the time of enrollment

CHICAGO, May 30, 2015 -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) and Baxter International's Bioscience business (BAX) today announced data from PERSIST-1 – a randomized Phase 3 registration-directed trial examining pacritinib for the treatment of myelofibrosis – in a late-breaking oral session at the 51^st Annual Meeting of the American Society of Clinical Oncology (ASCO), May 29-June 2, 2015 in Chicago, Ill. Pacritinib is an investigational oral multikinase inhibitor with specificity for JAK2 and FLT3.